Overview

NCI Definition: A high grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor. [1]

Endometrial serous adenocarcinomas most frequently harbor alterations in TP53, PIK3CA, PPP2R1A, FBXW7, and ERBB2 [2].

Most Commonly Altered Genes in Endometrial Serous Adenocarcinoma

TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Missense are the most common alterations in endometrial serous adenocarcinoma [2].

Top Alterations in Endometrial Serous Adenocarcinoma

Significant Genes in Endometrial Serous Adenocarcinoma

MLH1 +

MLH3 +

MSH2 +

MSH3 +

MSH6 +

PMS1 +

PMS2 +

POLE +

Disease Details

Synonyms
Uterine Corpus Serous Adenocarcinoma, Serous endometrial adenocarcinoma
Parent(s)
Endometrial Adenocarcinoma
OncoTree Name
Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma
OncoTree Code
USC

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.